These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37542276)

  • 1. The importance of clinical importance when determining the target difference in sample size calculations.
    Parker RA; Cook JA
    Trials; 2023 Aug; 24(1):495. PubMed ID: 37542276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimum important difference is minimally important in sample size calculations.
    Wong H
    Trials; 2023 Jan; 24(1):34. PubMed ID: 36650587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter?
    Hollingworth W; McKell-Redwood D; Hampson L; Metcalfe C
    Clin Trials; 2013 Feb; 10(1):43-53. PubMed ID: 23231969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA
    Sones W; Julious SA; Rothwell JC; Ramsay CR; Hampson LV; Emsley R; Walters SJ; Hewitt C; Bland M; Fergusson DA; Berlin JA; Altman D; Vale LD; Cook JA
    Trials; 2018 Oct; 19(1):542. PubMed ID: 30305155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter in response to: "The importance of clinical importance when determining the target difference in sample size calculations".
    Wong H
    Trials; 2023 Oct; 24(1):666. PubMed ID: 37828523
    [No Abstract]   [Full Text] [Related]  

  • 6. DELTA
    Cook JA; Julious SA; Sones W; Hampson LV; Hewitt C; Berlin JA; Ashby D; Emsley R; Fergusson DA; Walters SJ; Wilson ECF; Maclennan G; Stallard N; Rothwell JC; Bland M; Brown L; Ramsay CR; Cook A; Armstrong D; Altman D; Vale LD
    Trials; 2018 Nov; 19(1):606. PubMed ID: 30400926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power.
    Ambrosius WT; Polonsky TS; Greenland P; Goff DC; Perdue LH; Fortmann SP; Margolis KL; Pajewski NM
    Clin Trials; 2012 Apr; 9(2):232-46. PubMed ID: 22333998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trials 5: Determining the sample size and power for clinical trials and cohort studies.
    Greene T
    Methods Mol Biol; 2015; 1281():225-47. PubMed ID: 25694313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New guidance to improve sample size calculations for trials: eliciting the target difference.
    Bell ML
    Trials; 2018 Nov; 19(1):605. PubMed ID: 30396364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort Studies.
    Greene T
    Methods Mol Biol; 2021; 2249():281-305. PubMed ID: 33871850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the Delphi process to determine the minimum clinically important effect size for the Balanced-2 randomised controlled trial.
    Deng C; Sidebotham D
    Clin Trials; 2023 Oct; 20(5):473-478. PubMed ID: 37144615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Letter from Wong on determining the target difference in sample size calculations for randomised controlled trials.
    Cook JA; Parker RA
    Trials; 2024 Mar; 25(1):161. PubMed ID: 38431609
    [No Abstract]   [Full Text] [Related]  

  • 13. Sample size requirement to detect an intervention effect at the end of follow-up in a longitudinal cluster randomized trial.
    Heo M; Kim Y; Xue X; Kim MY
    Stat Med; 2010 Feb; 29(3):382-90. PubMed ID: 20014353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone graft substitutes for the treatment of traumatic fractures of the extremities.
    Hagen A; Gorenoi V; Schönermark MP
    GMS Health Technol Assess; 2012; 8():Doc04. PubMed ID: 22984371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting of statistical sample size calculations in publications of trials on age-related macular degeneration, glaucoma and cataract.
    Tulka S; Knippschild S; Funck S; Goetjes I; Uluk Y; Baulig C
    PLoS One; 2021; 16(6):e0252640. PubMed ID: 34086796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study.
    Teare MD; Dimairo M; Shephard N; Hayman A; Whitehead A; Walters SJ
    Trials; 2014 Jul; 15():264. PubMed ID: 24993581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations on sample size and power calculations in randomized clinical trials.
    Karlsson J; Engebretsen L; Dainty K;
    Arthroscopy; 2003 Nov; 19(9):997-9. PubMed ID: 14608320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size calculations for randomized clinical trials published in anesthesiology journals: a comparison of 2010 versus 2016.
    Chow JTY; Turkstra TP; Yim E; Jones PM
    Can J Anaesth; 2018 Jun; 65(6):611-618. PubMed ID: 29569142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI; Pile K; Hill CL
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.